The growth in pharma markets of emerging countries has outpaced the growth of developed countries' pharma markets. A number of factors such as epidemiological and economic shifts, demographic and strongly growing economy have boosted investments in the pharma markets of these countries. Among the emerging markets, E7 nations - Brazil, Russia, India, China, Mexico, Turkey and Indonesia - have done extremely well. As per our new research report "Emerging Pharmaceutical Markets Globally" the pharma markets in E7 countries is projected to grow at a CAGR of around 15% during 2010-2012.
The report further states that some macroeconomic factors are supporting the pharma markets in E7 countries. High GDP, per capita income and expenditure are key drivers of E7 pharma markets and the trend is expected to remain same in near future. In this regard, the report provides comprehensive analysis and detailed information of macroeconomic factors in E7 countries.
Besides, the report studies and analyzes various other factors like population growth, increase in ageing population, diseases profile of respective countries and healthcare spending pattern to provide an in-depth analysis of pharma markets. Moreover, the report contains authentic information about different segments of pharma industry like branded and generics, imported and domestically manufactured drugs.
"Emerging Pharmaceutical Markets Globally" is an outcome of extensive research and conceptual analysis of pharmaceuticals markets in emerging countries. The report provides result oriented evaluation of present and future industry trends. It contains thorough study of both macro and micro economic factors supporting the industry growth. The report also highlights certain emerging sectors which are growing in line with the development of pharma industries in E7 countries. The report will be a useful investment guide for those clients who are planning to invest in these countries.
For more information visit: http://www.rncos.com/Report/IM081.htm |
